Endovascular Today

Penumbra Begins FORWARD Study of Red Perfusion Catheter Portfolio in Distal Acute Ischemic Stroke Management

Penumbra, Inc. announced the initiation of its FORWARD study, which will collect safety and efficacy data on mechanical ...

Penumbra starts trial of clot removal device in stroke subgroup

Penumbra, which is set to become part of Boston Scientific this year, is running the trial to inform the treatment of a type of medium-vessel blockage.

FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke

Penumbra’s computer assisted vacuum thrombectomy platform uses aspiration for clot removal during acute ischemic stroke treatment.

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Isc…

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an ...
Business Wire

Independent Study Reaffirms Penumbra Aspiration as Frontline Thrombectomy Approach for Acute Ischemic Stroke

The COMPASS Trial results were featured in the main event plenary session at the International Stroke Conference and add to the growing body of evidence demonstrating Penumbra’s aspiration system is ...
Nasdaq

Penumbra (PEN) Gets FDA Nod for RED 62, Grows Thrombectomy Line

Penumbra, Inc. PEN recently received FDA clearance for the RED 62 Reperfusion Catheter. Following this regulatory go-ahead, the company has also initiated commercial availability of the catheter ...
Business Wire

Penumbra Launches Latest Advancements in Stroke Thrombectomy Aspiration Technology

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System’s most ...
Seeking Alpha

Penumbra outlines 13% to 15% revenue growth target for 2025 as thrombectomy adoption accelerates

Penumbra raised its full-year 2025 total revenue guidance to a range of $1.355 billion to $1.370 billion, targeting 13% to 15% growth. The company maintained guidance for U.S. thrombectomy growth at ...
Seeking Alpha

Penumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration

Lightning Bolt™ 7 is the most advanced arterial thrombectomy system on the market Latest technology combines modulated aspiration with superior catheter design to maximize blood clot removal in a ...
News Medical

Penumbra introduces new advancements in stroke thrombectomy aspiration technology

Penumbra, Inc., a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System's most advanced technology: Penumbra JET 7 and Penumbra ...
Investing

Penumbra’s SWOT analysis: thrombectomy leader’s stock poised for growth

Penumbra, Inc. (NYSE:PEN), a leader in the medical technology sector specializing in thrombectomy devices, has been garnering attention from analysts due to its strong performance and promising ...

Penumbra, Inc.: First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world ...